Effect of olmesartan medoxomil on cystatin C level, left ventricular hypertrophy and diastolic function

Blood Pressure

Volumn 18, Issue 4, 2009, Pages 187-191

  Albayrak, Sinan ^a   Ordu, Serkan ^a   Ozhan, Hakan ^a   Yazici, Mehmet ^a   Aydin, Mesut ^a   Alemdar, Recai ^a   Kaya, Ahmet ^a  

^a DUZCE UNIVERSITY   (Turkey)

Author keywords

Cystatin C; Hypertension; Left ventricular hypertrophy; Microalbuminuria

Indexed keywords

ALBUMIN; CREATININE; CYSTATIN C; OLMESARTAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MALE; ORGAN INJURY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CYSTATIN C; DIASTOLE; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; IMIDAZOLES; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; TETRAZOLES;

EID: 70849091229     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.1080/08037050903047236     Document Type: Article

References (29)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JLJr, et al. National Heart, Lung, and Blood Institute Joint National Committee on Pre vention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC7 report. JAMA. 2003;289:2560-2572.
2. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIREStudy Group. Cardiovascular prevention guidelines in daily practice: Acomparison of EUROASPIREI, II, and IIIsurveys in eight European countries. Lancet. 2009;373:929-940.
3. Levy D, Garrison RJ, Savage DD, kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Study. NEngl JMed. 1990;322:1561-1566. (Pubitemid 20176696)
4. Kannel WB, Dannenberg AL, Levy D. Population implications of electrocardiographic left ventricular hypertrophy. Am JCardiol. 1987;60:851-931.
5. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. Arch Intern Med. 1997;157:1413-1418.
6. Coll E, Botey A, Alvarez L, Poch E, Quintó L, Saurina A, et al. Serum cystatin Cas a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am JKidney Dis. 2000;36:29-34.
7. Shlipak MG, Sarnak MJ, katz R, Fried LF, Seliger SL, Newman AB, et al. Cystatin Cand the risk of death and cardiovascular events among elderly persons. NEngl JMed. 2005;352:2049-2060.
8. Jernberg T, Lindahl B, James S, Larsson A, Hansson LO, Wallentin L. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation. 2004;110:2342-2348.
9. Watanabe S, Okura T, Liu J, Miyoshi K, Fukuoka T, Hiwada K, et al. Serum cystatin Clevel is a marker of end-organ damage in patients with essential hypertension. Hypertens Res. 2003;26:895-899.
10. Mizuno M, Sada T, kato M, koike H. Renoprotective effects of blockade of angiotensin IIAT1 receptors in an animal model of type 2 diabetes. Hypertens Res. 2002;25:271-278.
11. Mussap M, Dalla Vestra M, Fioretto P, Saller A, Varagnolo M, Nosadini R, et al. Cystatin Cis a more sensitive marker than creatinine for the estimation of GFRin type 2 diabetic patients. Kidney Int. 2002;61:1453-1461.
12. Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, et al. Serum cystatin Cmeasured by automated immunoassay: a more sensitive marker of changes in GFRthan serum creatinine. Kidney Int. 1995;47:312-318.
13. Koenig W, Twardella D, Brenner H, Rothenbacher D. Plasma concentrations of cystatin Cin patients with coronary heart disease and risk for secondary cardiovascular events: morethan simply a marker of glomerular filtration rate. Clin Chem. 2005;51:321-327. (Pubitemid 40175801)
14. Djoussé L, Kurth T, Gaziano JM. Cystatin Cand risk of heart failure in the Physicians' Health Study (PHS). Am Heart J. 2008;155:82-86.
15. Watanabe S, Okura T, kurata M, Irita J, Manabe S, Miyoshi K, et al. Valsartan reduces serum cystatin Cand the renal vascular resistance in patients with essential hypertension. Clin Exp Hypertens. 2006;28:451-461.
16. Fujimoto S, Satoh M, Horike H, Hatta H, Haruna Y, Kobayashi S, et al. Olmesartan ameliorates progressive glomerular injury in subtotal nephrectomized rats through suppression of superoxide production. Hypertens Res. 2008;31:305-313.
17. Fliser D, Buchholz K, Haller H; EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Antiinflammatory effects of angiotensin IIsubtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation. 2004;110:1103-1107.
18. Haller H, Viberti GC, Mimran A, Remuzzi G, Rabelink AJ, Ritz E, et al. Preventing microalbuminuria in patients with diabetes: Rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. JHypertens. 2006;24:403-408.
19. Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes. 1995;44:1303-1309.
20. American Diabetes Association: Standards of Medical Care in Diabetes. Diabetes Care. 2002;25:33S-49S.
21. Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin IIreceptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ. 2004;329:828.
22. Ikeda H, Hamamoto Y, Honjo S, Nabe K, Wada Y, Koshiyama H. Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes. Diabetes Res Clin Pract. 2009;83:117-118.
23. Imai E, Ito S, Haneda M, Chan JC, Makino H; ORIENTInvestigators. Olmesartan reducing incidence of endstage renal disease in diabetic nephropathy trial (ORIENT): Rationale and study design. Hypertens Res. 2006;29:703-709.
24. Yasunari K, Maeda K, Nakamura M, Watanabe T, Yoshikawa J, Hirohashi K. Left ventricular hypertrophy and angiotensin IIreceptor blocking agents. Curr Med Chem Cardiovasc Hematol Agents. 2005;3:61-67.
25. Gerdts E, Roman MJ, Palmieri V, Wachtell K, Smith G, Nieminen MS, et al. Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study). JHum Hypertens. 2004;18:417-422. (Pubitemid 38787037)
26. Dahlöf B, Devereux RB, kjeldsen SE, Julius S, Beevers G, de Faire U, et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE ): a randomised trial against atenolol. Lancet. 2002;359:995-1003. (Pubitemid 34286536)
27. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, et al. LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE ): a randomised trial against atenolol. Lancet. 2002;359:1004-1010. (Pubitemid 34286537)
28. Julius S, kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. VALUEtrial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet. 2004;363:2022-2031.
29. Araujo AQ, Arteaga E, Ianni BM, Buck PC, Rabello R, Mady C. Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy. Am JCardiol. 2005;96:1563-1567. (Pubitemid 41690179)